Publication
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (11)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 11
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugAlpelisibcivic_curation1.00
- drugPalbociclibcivic_curation1.00
- drugPhosphatidylinositide 3-Kinase Inhibitorcivic_curation1.00
- drugRibociclibcivic_curation1.00
- geneCDK4civic_curation1.00
- genePIK3CAcivic_curation1.00
- geneRB1civic_curation1.00
- variantCDK4 EXPRESSIONcivic_curation1.00
- variantPIK3CA Mutationcivic_curation1.00
- variantRB1 PHOSPHORYLATIONcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25002028
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA Mutation2 | ||||||||
| Palbociclib + Phosphatidylinositide 3-Kinase InhibitorCombination | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1607Three PIK3CA mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941) by chronic exposure. Co-treatment of all three cell lines with PI3K inhibitor and CDK4/6 in… (full text at CIViC) PMID 25002028 · Vora et al., 2014 · Open in CIViC | civic |
| Phosphatidylinositide 3-Kinase Inhibitor + RibociclibCombination | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID1600Three PI3K mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941), and a panel of 42 inhibitor compounds was tested on the cells for ability to resensitize the… (full text at CIViC) PMID 25002028 · Vora et al., 2014 · Open in CIViC | civic |
| RB1 PHOSPHORYLATION1 | ||||||||
| Alpelisib | Malignant Breast Neoplasm | Predictive | B | Supports Resistance | 3 | accepted | EID1609The p110alpha-specific PI3K inhibitor BYL719 (Alpelisib) was used on a panel of five PI3K inhibitor sensitive and five resistant breast cancer cell lines. Sensitive cells (IC50<400nM) showed reduced p… (full text at CIViC) PMID 25002028 · Vora et al., 2014 · Open in CIViC | civic |
| CDK4 EXPRESSION1 | ||||||||
| Alpelisib | Estrogen Receptor-positive Breast CancerUNRESOLVED | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID264In mouse xenograft studies of PIK3CA mutant breast cancers, the combination of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions. PMID 25002028 · Vora et al., 2014 · Open in CIViC | civic |